
TL;DR
b.next has developed a manufacturing plant to produce Cytosol, essential for synthetic cell construction, overcoming significant supply chain challenges. Their open-access PURE system aims to enhance collaboration in synthetic cell engineering.
✦ Why It Matters
Explore open-access synthetic biology resources to enhance your projects and contribute to community-driven research.
Key Takeaways
Full Summary
b.next, a company focused on synthetic cell research, has developed a manufacturing plant to produce Cytosol, essential for constructing synthetic cells. Initially, the team faced significant challenges, including restricted access to necessary plasmids and the unavailability of tRNA, which hindered progress.
After redesigning and synthesizing an open-access set of PURE plasmids, they achieved a functional PURE system, confirming its viability. By mid-2025, they had optimized protocols for all PURE components and hosted workshops to disseminate this technology.
The manufacturing plant, operational since early 2026, has supplied over a hundred Cytosol kits to approximately 20 labs worldwide, facilitating collaborative research. This infrastructure is crucial for advancing synthetic cell technology and addressing global challenges.
Related